| 2008-01-11: |
cbm Responds to the Humanitarian Crisis in Kenya
Nairobi ( PRN/ots ) - cbm through its staff and Regional Office in Nairobi is providing emergency assistance to the humanitarian crisis in Kenya. It is estimated that around 500,000 people have lost their homes, due to the widespread violence following the disputed election. Prof. (...) |
| 2006-01-20: |
Quintiles Laboratory in Beijing Receives Two Key Certifications
Research Triangle Park, North Carolina ( PRN/ots ) - - CAP, NGSP focus on quality, standardization, safety Quintiles Transnational Corp. today announced that its central laboratory operation in China has earned two significant certifications - - one from the College of American Pathologists ( CAP ) and the other (...) |
| 2008-05-20: |
Inovelon( R ) a New Treatment for Lennox - Gastaut Syndrome Reduces Drop Attacks by Over 40%
London ( PRN/ots ) - - First EMEA Licensed Treatment Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, ( Headquarters: London, Chairman and CEO Yutaka Tsuchiya ) today announced publication of the results of a major study of its new anti - epileptic (...) |
| 2008-07-03: |
Movetis' Second Most Advanced Product Progresses to Phase IIb Trial Following Positive Results in Cirrhotic Ascites
Turnhout, Belgium ( PRN/ots ) - Movetis NV, a European specialist pharmaceutical company, today announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple - dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients (...) |
| 2008-07-07: |
Ferring Research Infertility and Gynaecology GrAnt ( FRIGGA ) 2008 Winners Announced
Barcelona ( PRN/ots ) - The winners of the Ferring Research Infertility and Gynaecology GrAnt ( FRIGGA ) are announced today at the European Society for Human Reproduction & Embryology Congress. The two winners of this new prize are the University Medical Centre Utrecht, The Netherlands and the (...) |
| 2006-07-12: |
New Indication for Breast Cancer Drug, Arimidex( TM ), Offers New Treatment Choice for Tamoxifen Patients in EuropeNew Indication for Breast Cancer Drug, Arimidex( TM ), Offers New Treatment Choice for Tamoxifen Patients in Europe
Macclesfield, England ( PRN/ots ) - - Thousands More Women Will Have the Opportunity to Take 'Arimidex' as Part of Their Breast Cancer Treatment and Improve Their Chances of Living Longer, Cancer Free - For Health Professional and Consumer Press - For International Journalists - Not for (...) |
| 2010-08-29: |
Multaq( R ) First - line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation
Paris, August 29, 2010 ( PRN/ots ) - Sanofi aventis announced today that the European Society of Cardiology ( ESC ) 2010 new Guidelines for the Management of Atrial Fibrillation ( AF ) have been released and recommend that Multaq( R ) ( dronedarone ) should be used for maintenance of sinus rhythm as (...) |
| 2010-09-12: |
Vandetanib Phase II Trial Shows Significant Improvement of Progression Free Survival in Patients With Advanced Papillary or Follicular Thyroid Cancer
Paris ( PRN/ots ) - AstraZeneca today announced results from a phase II study evaluating the investigational drug vandetanib for the treatment of patients with locally advanced or metastatic papillary or follicular thyroid cancer. This study, ZACTHYF, showed that treatment with vandetanib significantly improved Progression Free Survival (...) |
| 2005-10-31: |
Sanofi Pasteur Announces Agreement to License Novel Adjuvant From Eisai Co., Ltd
Lyon, France and Swiftwater, Pennsylvania ( PRN/ots ) - Sanofi pasteur, the vaccines business of the sanofi - aventis Group ( NYSE: SNY ), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to (...) |
| 2006-01-24: |
Quintiles Signs Agreement to Join Pharma Commercialization Joint Venture in Asia Pacific
Research Triangle Park, North Carolina ( PRN/ots ) - - Quintiles to partner with Interpharma Asia Pacific and Temasek Holdings Limited - JV to have US$112 million investment fund to expand pharmaceutical sales in Asia Pacific Quintiles Transnational Corp. today announced that it (...) |
| 2004-10-07: |
The FDA has Granted Orphan Drug Status to Yondelis for the Treatment of STS
Madrid ( PRN/ots ) - The United States Food & Drug Administration ( FDA ) has granted Orphan Drug Designation to Yondelis in the indication of Soft Tissue Sarcoma ( STS ). The sponsor of this application in the US is our partner Johnson & Johnson Pharmaceutical Research & Development. (...) |
| 2011-04-21: |
Pevion's shareholders elect Jean - Paul Prieels, former Head Research GSK Vaccines, to its Board
Ittigen / Bern, Switzerland ( na Originaltextservice ) - Pevion Biotech AG today announced that Jean - Paul Prieels has joined its Board of Directors. Until January 2011, Dr. Prieels was Senior Vice President Research and Development at GlaxoSmithKline Biologicals. Jean - Paul Prieels joined GlaxoSmithKline (...) |
| 2008-09-08: |
Sanofi Aventis: New Real Life Studies Illustrate Greater A1C Lowering and Cost Benefit Observed With LANTUS( R ) Over Detemir and NPH Insulin
Paris ( PRN/ots ) - - The THIN, ROLE and LIVE - DE Studies Used Medical Databases or Medical Records to Compare the Benefits of Different Insulin Treatments in Thousands of People Living With Type 2 Diabetes - Abstracts 1000, 1001 and 1004 Sanofi - aventis, a (...) |
| 2008-11-01: |
New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
Basel, Switzerland, November 1 ( PRN/ots ) - A new, independently - conducted study being presented at AASLD shows that PEGASYS( R ) ( peginterferon alfa - 2a ( 40KD ) ) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.( 1 ) Comparing Today's Standard Treatment Regimens: (...) |
| 2007-04-16: |
Roche's Anaemia Therapies to Feature Strongly at Upcoming World Congress of Nephrology
Basel, Switzerland ( PRN/ots ) - Nephrologists attending the upcoming World Congress of Nephrology ( WCN ) in Rio de Janeiro, Brazil 21 - 25 April will hear about a wide range of study results from Roche's robust renal anaemia clinical trial programs for its two treatments - - MIRCERA( R ) and (...) |
| 2007-07-19: |
European Medicines Agency Accepts Review of Marketing Authorization Application for New Antibiotic Doripenem
Beerse, Belgium ( PRN/ots ) - Janssen - Cilag International NV announced today that the European Medicines Agency ( EMEA ) has accepted for review a Marketing Authorization Application ( MAA ) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia ( NP ), including ventilator - associated pneumonia ( VAP ), complicated intra - (...) |
| 2009-12-18: |
Amgen Receives CHMP Positive Opinion for Prolia( TM ) ( Denosumab ) in the European Union
Thousand Oaks, California ( PRN/ots ) - Amgen Inc. today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has announced a positive opinion for the marketing authorization of Prolia( TM ) ( denosumab ) for the treatment of osteoporosis in postmenopausal (...) |
| 2008-07-29: |
SemBioSys Submits IND for Safflower - Produced Insulin to U.S. FDA
Calgary ( PRN/ots ) - - Submission Demonstrates Progress of Plant - Derived Insulin Program Scheduled to Enter the Clinic Later This Year SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it (...) |
| 2008-02-04: |
Acrongenomics Acquires Equity Stake in Molecular Vision
Geneva ( PRN/ots ) - Acrongenomics, Inc. ( OTC: AGNM ) is pleased to announce that they have acquired a 10.9 Prozent interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its (...) |
| 2006-08-09: |
Go - ahead for the Scientific Award 2007 / The BMW Group offers support worth EUR 70,000 to talented young researchers from all disciplines worldwide
Munich ( na Originaltextservice ) - The BMW Group is inviting young academics from all over the world to submit their entries for the prize for up - and - coming scientists - the Scientific Award 2007. The motto of the award is "Passion for Innovation", and prizes are presented (...) |
| 2006-11-17: |
Study of Over 33,000 Women Comparing Two Most Prescribed Osteoporosis Treatments Shows Significant Difference in Hip Fracture Reduction
Paris, November 17 ( PRN/ots ) - - Actonel Almost Halves the Risk of Breaking a Hip When Compared to Alendronate in the First Year of Treatment - For Non - US Journalists Only Data published today from a retrospective study of over 33,000 postmenopausal women (...) |
| 2008-12-04: |
Results From the First and Largest Collaborative Study Confirm Role of Enbrel( R ) in Psoriatic Arthritis
Maidenhead, England ( PRN/ots ) - - New Data Add to the Body of Evidence That Show That Enbrel ( Etanercept ) Clears Skin and Can Sustain This Efficacy Over Time New data presented today at the 'Gene to Clinic' meeting taking place at the Royal (...) |
| 2009-09-25: |
Sanofi Aventis : Multaq( R ) ( dronedarone ) Recommended for Approval in the European Union
Paris ( PRN/ots ) - Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for (...) |
| 2008-12-12: |
Agendia's MammaPrint( R ) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint( R )'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the (...) |
| 2006-06-13: |
Optimized use of Atypical Antipsychotics Associated With Equal Efficacy and Brief Hospital Stays in Patients With Acute Psychosis
Victoria, Australia ( PRN/ots ) - A new study published by physicians from the Mental Health Research Institute and Monash University of Victoria, Australia, showed that all atypical antipsychotics studied were equally efficacious when used at optimal doses as primary medication for inpatients with acute psychosis.( 1 ) They (...) |
| 2009-09-21: |
Value of Text Verification Tool ( TVT ) Strongly Confirmed at RAPS in Philadelphia
Frankfurt ( na Originaltextservice ) - Trying economic times mean tight budgets. More projects, fewer people, rigid quality standards and competitve pressures are making the computer - driven proofreading tool made by Schlafender Hase more valuable than ever. Schlafender Hase GmbH of Frankfurt reported that (...) |
| 2008-02-13: |
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Basel, Switzerland ( PRN/ots ) - - Results of This Trial Further Confirm the Benefit Avastin Brings to Patients With Breast Cancer. Roche announced today that a phase III study in metastatic breast cancer investigating Avastin ( bevacizumab ) in combination with docetaxel chemotherapy compared to docetaxel (...) |
| 2006-11-13: |
New Study Indicates Boosted Invirase 500 Patients Achieve Similar Levels of Viral Suppression to Boosted Lopinavir but with a Better Lipid Profile
Glasgow, Scotland, November 13 ( PRN/ots ) - - Patients Treated With Boosted Invirase 500 Were Significantly Less Likely to Develop Elevated Lipids Than Boosted Lopinavir Promising head to head results presented today indicate that the boosted protease inhibitor ( PI/r ) Invirase 500/r (...) |
| 2004-12-03: |
Moulin and Golden Gate Capital Acquire Eye Care Centers of America, the Second Largest Optical Retail Chain in the US
Hong Kong ( PRN/ots ) - - Integrates the Largest Frame Manufacturer in Asia with the Most Powerful Value Proposition in the US Retail Market Moulin International Holdings Limited ( "Moulin" / the "Group" )( stock code: 389 ), a global leader in the manufacturing, distribution and retailing of eyewear, (...) |
| 2008-12-14: |
Xeloda Shows Strong Promise in Early Breast Cancer
San Antonio, Texas ( PRN/ots ) - - FOR NON - US DOMESTIC and NON - UK journalists only - Early Data Indicate Chemotherapy Pill Xeloda, Already Proven in Advanced Breast Cancer, May Also Reduce Recurrence of Early Breast Cancer Data presented today indicate that adding Xeloda (...) |
| 2005-12-08: |
Press Conference Invitation from AstraZeneca at the San Antonio Breast Cancer Symposium 2005
Macclesfield, England ( PRN/ots ) - 'New Data Outcomes in Early Breast Cancer: Improving the Odds for Survival' News that could change the landscape for hormonal treatments in postmenopausal women Room: 0001B, River Level, Henry B. Gonzalez Convention Center, San (...) |
| 2010-06-07: |
ArQule And Daiichi Sankyo Present Final Phase 2 Results For ARQ 197 C - Met Inhibitor in Non - Small Cell Lung Cancer at ASCO
Woburn, Massachusetts and Tokyo, June 7, 2010 ( PRN/ots ) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. ( TSE 4568 ) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology ( ASCO ) (...) |
| 2007-11-22: |
Bangladesh Cries for our Help
Toronto, November 22 ( PRN/ots ) - "CBM urgently needs help for the most vulnerable people affected by the recent flooding in Bangladesh," says Prof. Allen Foster President of CBM. The latest report says the death toll in the fiercest cyclone to hit Bangladesh's (...) |
| 2008-11-10: |
Unique New Initiative by World - Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
New Orleans and Los Angeles, November 10 ( PRN/ots ) - - Current Treatment Fails to Abolish Majority of Vascular Risk - Residual Risk Reduction Initiative ( R3i ) Calls for Action to Reduce the Lipid - Related Residual Vascular Risk Unaddressed by Current Standards of Care in (...) |
| 2007-11-29: |
First European Patient Treated in CABERNET Trial with Novel Treatment for Wet AMD
Leipzig, Germany, November 29 ( PRN/ots ) - - Ophthalmic Clinic in Germany First in Europe To Treat Patients With New Focused Radiation Therapy NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for (...) |
| 2009-03-31: |
Wyeth Submits Marketing Application to FDA for its 13 - Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
Collegeville, Pennsylvania ( PRN/ots ) - - Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has submitted a Biologic License Application ( BLA ) to the U.S. (...) |
| 2006-05-23: |
Treating Both Poles of Bipolar Disorder: Pivotal Study Confirms Potential of Quetiapine as First Atypical Antipsychotic Monotherapy
Toronto ( PRN/ots ) - - For Healthcare and Medical Reporters ( non - US and non - UK ) The results of a pivotal study confirm the potential of quetiapine fumarate ( SEROQUEL ) as a monotherapy ( treatment with a single antipsychotic medicine ) for acute bipolar depression. Quetiapine is an (...) |
| 2005-10-06: |
Nationwide Strengthening of Hospital System in Tanzania Marks New Era in Fight Against AIDS in Africa
Dar Es Salaam, Tanzania ( PRN/ots ) - - The Abbott Fund and the Government of Tanzania Dedicate New Hospital Facilities to Meet Long - Term Needs of Patients with HIV/AIDS and Other Diseases In a ceremony today, Abbott CEO Miles White joined Tanzanian President (...) |
| 2007-04-13: |
SEBIVO( R ) Demonstrated Better Antiviral Activity Compared to Adefovir in Patients With Chronic Hepatitis B; New Data Presented
Barcelona, Spain ( PRN/ots ) - - SEBIVO Suppressed Virus More Rapidly and Profoundly Than Adefovir( 1 ) - Rapid and Powerful Viral Suppression Led to Better Treatment Outcomes( 2 ) - SEBIVO Has Been Recommended for Approval by European Medicines Agency, Pending Final Approval by the European Commission In a (...) |
| 2007-12-10: |
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX - 208
Calgary, Canada ( PRN/ots ) - - New Class of ApoA - I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ( "Resverlogix" ) ( TSX:RVX ) announced today that it has received approval by the US Food and Drug Administration ( FDA ) to initiate a Phase 1a (...) |
| 2010-01-07: |
Tolerx Completes Enrollment in DEFEND - 1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Cambridge, Massachusetts ( PRN/ots ) - Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND - 1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new - onset autoimmune type 1 diabetes. (...) |
| 2006-01-18: |
STMicroelectronics and Veredus Laboratories Team to Diagnose Avian Flu Using Rapid - Detection Point - of - Need Lab - on - Chip
Geneva and Singapore ( PRN/ots ) - STMicroelectronics ( NYSE: STM ) and Veredus Laboratories today announced that they are developing a fast, point - of - need diagnostic capability that will enable health practitioners to quickly detect strains of Avian Flu and other influenza viruses. The diagnostic capability, (...) |
| 2005-10-04: |
Invitation to the "Degussa Meets Science" event
Düsseldorf ( na Originaltextservice ) - - Cross - reference: A description of starting to the Science to Business Center and a reply coupon is available at http://www.presseportal.de/dokumente.html To Members of the Business, Science and Chemical Press Dear Sir/Madam, (...) |
| 2007-06-18: |
Advagraf( R ) Now Available in Germany and the UK as a Once - Daily Immunosuppressant in Organ Transplantation
London ( PRN/ots ) - Astellas today announced that Advagraf( R ) ( generic name: tacrolimus, prolonged release ), a once - daily immunosuppressant for use in organ transplantation, is now available in Germany and the UK. The European Commission approved Advagraf( R ) on April 23, 2007 for the prophylaxis of transplant (...) |
| 2008-10-07: |
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
KVISTGÅRD, Denmark, October 7 ( PRN/ots ) - - 125 Patient, Prospective Randomized Placebo - Controlled Phase II Study Shows Statistically Significant Improved Overall Survival KVISTGÅRD, Denmark, October 7 /PRNewswire/ - - Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer (...) |
| 2009-06-02: |
IMPACT Study Shows Longer Valcyte Treatment Provides Better Protection Against Cytomegalovirus ( CMV ) Disease CMV is the Most Serious Viral Infection Affecting Transplant Patients
Basel, Switzerland ( PRN/ots ) - - For Non - US Media Only New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 ( ATC ) demonstrate that doubling the duration of preventive therapy ( 'prophylaxis' ) with Valcyte ( oral valganciclovir ), (...) |
| 2010-12-20: |
Daiichi Sankyo Announces First European Approval for Sevikar HCT( R ), a New Three - in - one Combination Product for the Treatment of High Blood Pressure*
Munich ( PRN/ots ) - Daiichi Sankyo Europe announced today that Sevikar HCT( R ) is now approved in Germany, the first market to launch this new once - daily three - in - one combination product for the treatment of high blood pressure ( BP ). This new drug combines the three (...) |
| 2005-09-14: |
Isotechnika Announces Ninety Per Cent Participation in Phase III Psoriasis Extension Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) announced today the participation level in its Canadian Phase III psoriasis extension trial for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy (...) |
| 2011-02-10: |
Zebinix, Novel Once - Daily Anti - Epileptic Treatment, Launches in Spain
Hatfield, England ( PRN/ots ) - Zebinix( R ) ( eslicarbazepine acetate ), an add - on ( adjunctive ) therapy for adults with partial - onset seizures, with or without secondary generalisation ( where the seizure spreads to both sides of the brain ), has been launched today in Spain by Eisai and BIAL in (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
